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We have investigated the effect of mAMSA, a potent topoisomerase II inhibitor, on the c-myc proto-oncogene of the acute promyelocytic leukemia 
HL60 cell line during its differentiation. When HL60 cells were induced by dimethylsulfoxide (DMSO) to terminally differentiate, a rapid drop 
m the level of c-myc mRNA was observed, followed by an arrest of cell proliferation. In contrast, the level of topoisomerase II mRNA was transiently 
Increased with a maximum at 6 h after DMSO addition and was then completely abolished after 48 h, indicating that topoisomerase II is activated 
during the onset of HL60 differentiation. In exponentially growing cells, treatment by mAMSA results in the formation of topoisomerase 
II-mediated double strand DNA breaks in the c-myc gene at positions where topoisomerase II would normally nick and reseal the two strands. 
In HL60 cells treated with both mAMSA and DMSO, the sites in the c-myc gene at which mAMSA had induced cleavage were not altered. However, 
a DNA cleavage site located at the end of the first c-myc exon (position +3100), was strongly stimulated by mAMSA and DMSO treatment. This 
site fell within a DNase I hypersensitive region encompassing the MYC intron factor 1 (MIFl) binding site, where transcription elongation is 
normally blocked during differentiation. These data indicate that a change of topoisomerase II binding to critical regulatory region of the c-myc 
gene is associated with the downregulation of this gene during differentiation. 
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1. INTRODUCTION 
The c-myc proto-oncogene plays a central role in the 
control of cell proliferation and differentiation [1,2]. 
Large variations in c-myc RNA levels occur during ter- 
minal differentiation [ 1,2] and mitogenic stimulation of 
quiescent cells [2-51. The deregulation of c-myc expres- 
sion, frequently observed in cancer cells, can be caused 
by gene amplification, chromosomal translocation, 
retroviral insertion or point mutation [1,2]. c-myc ex- 
pression is controlled by different mechanisms, includ- 
ing change in transcription initiation or elongation, and 
mRNA stability [4,6,7]. Several positive and negative 
control elements located in the 5’ flanking region and 
in the vicinity of the promoter region have been shown 
to regulate the transcription of c-myc [8-lo]. 
DNA topoisomerases are enzymes that solve the 
DNA topological problems linked to transcription, rep- 
lication and chromosomal segregation during cell divi- 
sion [l 11. Eukaryotic topoisomerase II is the cellular 
target of a variety of anticancer drugs, including 
mAMSA and etoposide [12]. These drugs poison topo- 
isomerase II by stabilizing enzyme-DNA cleavage com- 
plexes [12]. Previous studies, in which specific topoisom- 
erase II inhibitors were used as probes, have indicated 
that in the c-myc gene the DNA cleavage mediated by 
topoisomerase II occurs at specific positions corre- 
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sponding to important regulatory elements located in 
accessible regions of the c-myc chromatin [13-l 51. DNA 
cleavage induced by mAMSA in the 5’ region is also 
increased with the c-myc mRNA steady state level, cor- 
responding to increased gene transcriptional accessibil- 
ity [16]. 
In the present study, we have mapped the cleavage 
sites of topoisomerase II in the c-myc proto-oncogene 
of terminally differentiated and undifferentiated HL60 
cells. We have identified a new topoisomerase II cleav- 
age site near the MIFl binding site, suggesting that 
topoisomerase II participates in the c-myc transcrip- 
tional regulation which occurs during cell differen- 
tiation. 
2. MATERIALS AND METHODS 
2.1. Drugs 
mAMSA (4’-(9-acridinylamino)-methansulfon-m-anisidide) was
obtained from Substantia Laboratory (Parke Davis Division, 
Courbevoie, France). Drug stock solution in DMSO at 10 mM was 
prepared immediately before use. Further dilutions were made in 
deionized water. DMSO was purchased from Sigma Chemicals. 
2.2. Cell lines and culture conditions 
The human promyelocytic leukemia cell line HL60 was obtained 
from the American Type Culture Collection (Rockville, MD, USA). 
Cells were grown in suspension culture at 37’C under 5% CO, in a 
humidified atmosphere, in RPM1 1640 medium supplemented with 
15% heat-inactivated fetal calf serum, 2 mM L-glutamine and 5O&mI 
gentamycin as described previously [17]. Cell growth was determined 
by Trypan blue dye exclusion. 
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2.3. Northern blot analysis 
About 10’ HL60 cells were treated for the indicated time with 1.25% 
DMSO. Total cellular RNA was prepared by the guanidinium isothio- 
cyanate/CsCl density gradient fractionation method [18]. Ten pg of 
each RNA sample were electrophoresed on a 1% agarose gel contain- 
ing formaldehyde transferred to a Hybond N’ membrane (Amersham) 
and hybridized with the c-myc, topoisomerase II or /7-actin probes. 
Membranes were washed under stringent conditions as described pre- 
viously [18]. DNA/RNA hybrids were revealed by autoradiography on 
Amersham MP hyperfilms. Signals were quantified by densitometry 
(Pharmacia LKB uhroscan XL) and results normalized against /I- 
actin. 
2.4. In vivo analysis of topoisomerase II cleavage sites 
About lo6 HL60 cells in the exponential phase of growth were 
treated for the indicated time with 1.25% DMSO and were exposed 
to 5 PM mAMSA for 30 min at the end of the DMSO treatment. Cells 
were washed with 50 mM Tris-HCI, pH 7.51 mM EDTA and imme- 
diately lysed with 1% SDS, 50 mM Tris-HCI, pH 7.5,25 mM EDTA. 
Proteinase K was added to a final concentration of 0.5 mg/ml and cells 
were incubated for 12 h at 5O’C. Lysates were then treated with 
phenol, phenol+hloroform and chloroform, dried and resuspended in
Tris-HCl, pH 7.5.0.5 mM EDTA at a concentration of 2 mg/ml. DNA 
(1Opg) were digested with EcoRI restriction endonuclease and electro- 
phoresed in 1.2% agarose gel. DNA fragments were transferred onto 
a Hybond N’ membrane (Amersham) and hybridized with the c-myc 
probe. Hybrids were revealed after 48 h by autoradiography on hyper- 
film MP. Analysis of peak intensity was done by densitometry using 
the Pharmacia LKB Ultroscan XL apparatus, and band size was 
determined using a specific computer program of the Ultroscan XL, 
with fragments of phage I DNA digested with Hind111 used as internal 
markers. 
2.5. Probes 
The probes used were the 1.4 kb ClaI-EcoRI insert of the human 
c-myc third exon [19], the 1.8 kb EcoRI insert of the human topoisom- 
erase Ha cDNA [20] and the 1.15 PstI insert of the murinep-actin gene 
[21]. Probes were nick-translated with [a-‘*P]dATP and dCTP (3000 
Ci/mmol, Amersham) to a specific activity of 5 x IO8 dpm/pg. 
3. RESULTS 
HL60 cells consist of a majority of promyelocytes 
which differentiate into functionally and morphologi- 
cally mature granulocytes in response to DMSO treat- 
ment. According to Collins et al. [ 171, HL60 cells treated 
for 48 h with 1.25% DMSO stop dividing, become 
strongly adherent on culture dish and undergo morpho- 
logical changes, but 95% remain viable, when viability 
is assessed by Trypan blue dye exclusion. 
To determine the level and kinetics of c-myc and to- 
poisomerase II transcription during differentiation, 
HL60 cells were induced to differentiate with DMSO, 
and RNA was extracted at various times afterwards. 
Equal amounts of RNA were transferred to nitrocellu- 
lose filters and probed with c-myc, topoisomerase II and 
B-actin. The results, presented in Fig. 1, showed that 3 h 
after the induction of differentiation, the c-myc mRNA 
level had nearly disappeared and remained low 48 h 
following the DMSO treatment. Topoisomerase II 
mRNA level was found to be 2-fold increased at 6 h 
after the addition of DMSO and then was progressively 
decreased until a complete disappearance at 48 h 
(Fig. 1). 
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Fig. 1. Relative c-myc and topoisomerase II mRNA levels in HL60 
cells during differentiation. HL60 cells were induced to differentiate 
with 1.25% DMSO for the indicated time and RNA extracted. Ten ,ug 
of RNA were electrophoresed, transferred on Hybond N’ and hybrid- 
ized with the c-myc, topoisomerase II and p-actin probes (see section 
2). Peak intensity of the mRNA signals were quantified by densitom- 
etry on the autoradiograms (Ultroscan XL) and values were normal- 
ized with the B-actin values. Results are expressed relative to the 
mRNA level of DMSO-untreated HL60 cells (defined as 1). 
In order to determine whether DMSO-induced 
downregulation of c-myc gene may alterate the in vivo 
topoisomerase II cleavage sites, we have examined here 
the c-myc DNA from HL60 cells treated with mAMSA 
as already described [13]. When DNA from untreated 
HL60 cells was digested with EcoRI and probed with 
the 1.4 kilobase pairs EcoRI-ClaI fragment of c-myc, a 
13 kilobase DNA band was deteced (Fig. 2, lane 1) 
which is markedly amplified, as previously described 
[4]. The DNA pattern from mAMSA-treated HL60 cells 
during the exponential phase of growth (Fig. 2, lane 2) 
showed additional DNA bands of lower molecular 
weight, indicating the presence of topoisomerase II 
sites, as already described [13,14]. The c-myc DNA, 
prepared from HL60 cells at different times (0, 3, 6, 24 
and 48 h) after DMSO treatment (Fig. 2, lanes 3-7) had 
no cleavage sites and were comparable to that of control 
untreated HL60 cells (lane 1). When HL60 cells were 
treated for 30 min with 5 PM mAMSA at different times 
after the addition of DMSO (3,6,24 and 48 h, see lanes 
8, 9, 10 and 11, respectively), the c-myc DNA cleavage 
pattern was modified: mAMSA strongly stimulated 
DNA cleavage at a site located in the intro between 
exons 1 and 2 (indicated by an arrowhead). This cleav- 
age site was barely detectable in non-differentiated cells, 
treated with mAMSA (lane 1). 
In order to quantify and to localize more precisely the 
new site induced in c-myc, the autoradiogram shown in 
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Fig. 2. In vivo DNA cleavage sites induced by mAMSA in the c-myc 
gene during differentiation. Control untreated HL60 cells (lane 1). 
Undifferentiated HL60 cells treated with 5 PM mAMSA for 30 min 
(lane 2). HL60 cells treated with 1.25% DMSO for the indicated time 
(&48 h) are presented in lanes 3-7. HL60 cells differentiated with 
1.25% DMSO for the indicated time (348 h) and treated with 5 PM 
mAMSA for 30 min at the end of the DMSO treatment are presented 
in lanes 8-l 1. After treatment, cells were lysed by SDS and DNA 
extracted (see section 2). DNA samples (10 pg) were digested with 
EcoRI. transferred on Hybond N’ and hybridized with the c-myc 
probe. Arrowhead indicated the topoisomerase II cleavage site in- 
duced during differentiation. Schematic map of the c-myc gene is 
presented on the right. 
Fig. 2 was scanned with a laser densitometer. The den- 
sitometric tracing of the c-myc gene obtained from un- 
treated HL60 (lane l), mAMSA- or mAMSA plus 
DMSO-treated HL60 cells (lanes 2 and 11, respectively) 
are shown in Fig. 3. The intensity of the cleavage was 
normalized relatively to the 13 kilobase c-myc DNA 
band from untreated HL60 cells. The mAMSA cleavage 
site stimulated by DMSO treatment was localized 
around position +3100 + 200 base pairs from the up- 
stream Hind111 site, according to the sequence pub- 
lished by Gazin et al. [22]. The analysis also indicated 
that the intensity of cleavage induced by mAMSA at 
position +3100 was equal to 19.5% and 3.5% of the total 
c-myc gene cleavage generated for differentiated or un- 
differentiated HL60 cells, respectively. After DNA con- 
tent normalization, the other DNA cleavage sites stimu- 
lated by mAMSA did not have intensities ignificantly 
modified by the DMSO treatment. 
4. DISCUSSION 
Earlier studies have shown that the activity of topo- 
isomerase II is significantly affected by the growth state 
of the cell [23]. Differentiation can be induced chemi- 
cally in several human and murine leukemia cell lines 
and is associated with a significant decrease in topo- 
isomerase II activity [24,25] and mAMSA-induced 
DNA protein crosslinks [26,27]. Early events such as 
c-myc gene downregulation have also been described 
[3,4]. In accordance with these studies we found that 
treatment of HL60 cells with 1.25% DMSO for 48 h led 
to a complete disappearance of the c-myc and topoisom- 
erase II gene transcripts. However, while c-myc 
downregulation occurs within 3 h after the differentia- 
tion induction, topoisomerase II downregulation ap- 
pears to be a later event. Our results also indicated that 
the topoisomerase II mRNA level is transiently in- 
creased, with a maximum at 6 h after the start of the 
differentiation. Due to the important functions of topo- 
isomerase II during replication, transcription and mito- 
sis [11,12], the topoisomerase II decrease at 48 hours 
would probably correspond to the arrest of the cell 
proliferation, while the transient topoisomerase II in- 
crease would reflect transcriptional processes activated 
at the differentiation onset. 
The present study also demonstrated that mAMSA 
altered the DNA cleavage patterns in the c-myc proto- 
oncogene during DMSO-induced differentiation. Inter- 
estingly, the pre-existing topoisomerase II cleavage sites 
in the c-myc gene, detected uring the exponential phase 
of growth of HL60 cells, were not greatly modified by 
mAMSA during the time course of DMSO-induced dif- 
ferentiation. However, mAMSA induced cleavage at a 
distinct additional site which corresponds to the begin- 
ning of the first intron in the c-myc locus, 3100 base 
pairs from the start of the gene. Furthermore, in previ- 
ous in vitro studies, a strong mAMSA-induced cleavage 
site had been mapped at this position by using purified 
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Fig. 3. Densitometric scan of the c-myc DNA electrophoretic pattern 
presented in Fig. 2: control untreated HL60 cells (. . .). undifferenti- 
ated HL60 cells treated with 5 PM mAMSA (------), differentiated 
HL60 cells (48 h) treated with 5 PM mAMSA (-). The intensity of 
the curves were normalized relatively to the 13 kilobase pairs (EcoRI- 
EcoRI) c-myc DNA band from untreated HL60 cells. The x-Axis 
indicate the DNA marker scale in kilobase and the position of some 
restriction enzyme sites in the c-myc gene (R = EcoRI, H = HindHI, 
X = X&I, B = BumHI, and C = ClaI). The y-Axis indicate the opti- 
cal density. Band size and peak intensity analysis were determined 
using the Pharmacia LKB Ultrascan XL programs. Arrow and num- 
ber indicate the topoisomerase II cleavage site induced during differ- 
entiation and its position in base pairs relatively to the Hind111 site, 
according to the sequence published by Gazin et al. [22]. 
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topoisomerase II and c-pnyc DNA [15,28]. These data 
indicate that a potential topoisomerase II cleavage site, 
which is masked during the growth of untreated HL60 
cells, is revealed by mAMSA during the differentiation 
process. In previous studies, we reported that the topo- 
isomerase II cleavage sites located in the 5’ non-coding 
region of the c-myc gene are associated with the in- 
creased gene transcription, reflecting the accessibility of 
this portion of the chromatin to topoisomerase II [13- 
16]. Our present results indicate that a different topo- 
isomerase II cleavage site is associated with the tran- 
scriptional downregulation of the c-myc gene during 
DMSO-induced differentiation. In fact, the first half of 
c-myc intron 1 has been implicated as a negative tran- 
scription regulatory region for this gene [8]. Interest- 
ingly, the topoisomerase II cleavage site identified here 
was located within the DNA binding site of the MIFl 
(Myc intron factor 1) [29], which has been identified as 
a methylated DNA-binding protein [30]. This element 
was frequently found to be mutated in Burkitt’s lym- 
phoma and these mutations have been implicated in the 
deregulation of c-myc gene tran~ription 131,321. A
DNase I hypersensitive site located about 300 base pairs 
downstream from the 5’ end of the first intron (position 
+3200) also appears during HL60 differentiation, and 
the decreased c-myc transcription was shown to be due 
to a block of the elongation of the transcript in this 
region [4]. 
In conclusion, these data suggest hat topoisomerase 
II is associated uring differentiation with this negative 
regulatory region of c-myc and may participate to the 
its transcriptional regulation. 
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